Infinity Clinical Research LLC

1. Novartis Pharmaceuticals Corporation $2,752,336 34 payments
2. Eli Lilly and Company $2,286,524 78 payments
3. Genentech, Inc. $662,419 50 payments
4. Biogen, Inc. $504,536 4 payments
5. Sage Therapeutics, Inc. $376,470 20 payments
6. Eisai Inc. $345,347 73 payments
7. Genzyme Corporation $285,443 66 payments
8. Amneal Pharmaceuticals LLC $236,473 58 payments
9. Allergan Inc. $201,437 46 payments
10. ACADIA Pharmaceuticals Inc $115,684 24 payments

1. An Open Label Study to Assess Response to Influenza Vaccine in Ofatumumab Treated Patients. $709,974 4 payments
2. A Single-Arm, Prospective, Multi-Center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-Cd20 Monoclonal Antibody (Acd20 Mab) Therapy (Olikos) $679,784 5 payments
3. An Open-Label Multicenter Study to Assess Response to Covid-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 MG Subcutaneously $515,508 4 payments
4. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $494,993 3 payments
5. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $477,989 7 payments
6. Gantenerumab in Early Ad $476,470 19 payments
7. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $455,132 10 payments
8. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $416,286 7 payments
9. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $345,347 73 payments
10. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $340,435 2 payments

1. Patient care $28,474 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.